You are here: Home > News > Clinical Trial News

Clinical Trial News

View our most recent news stories below, or view our archive

Week 19, May 2013

PSI met an interim enrollment milestone of 100 randomized patients in a phase III study of a novel antiarrhythmic for the treatment of atrial fibrillation.
PSI completed the active treatment period in a phase III study of a novel biological agent in patients with hemophilia B.
PSI completed a phase III study of a novel antineoplastic agent in patients with bladder cancer.
PSI completed a phase II study of a novel biological agent in patients with metastatic non-small cell lung cancer (NSCLC).
PSI completed a phase II study of a novel biological agent in patients with psoriasis.

	Week 18 PSI launched a phase III study of a novel biological agent in patients with hemophilia.

	Week 17 PSI launched a phase III study of a novel antibiotic in patients with complicated intra-abdominal infections (cIAI).

	Week 16 PSI launched a phase II study of a novel antineoplastic agent in patients with solid tumors.

	Week 15 PSI launched a phase II study of a novel biological agent in patients with metastatic breast cancer.

	Week 14 PSI initiated enrollment in a phase III study of a novel antithrombotic agent in patients atrial fibrillation.

	Week 13 PSI launched a phase III study of a novel biological agent in patients with hemophilia A.

	Week 12 PSI initiated enrollment in a phase III study of a novel antibiotic in pediatric patients with community-acquired bacterial pneumonia (CABP).

	Week 11 PSI initiated enrollment in a phase III study of a novel biological agent in patients with advanced non-small cell lung cancer (NSCLC).

	Week 10 PSI completed the active treatment period in a phase II study of a novel biological agent in patients with psoriasis.

	Week 9 PSI initiated enrollment in a phase III study of a novel biological agent in patients with severe sepsis.

	Week 8 PSI launched a phase III study of a novel antihyperglycemic in patients with type 2 diabetes.

	Week 7 PSI met an interim enrollment milestone of 50 randomized patients in a phase II study of a novel biological agent in advanced non-small cell lung cancer (NSCLC).

	Week 6 PSI launched a phase II dose-ranging study of a novel product for the treatment of asthma.

	Week 5 PSI launched a phase II dose-ranging study of a novel product for the treatment of asthma.

	Week 4 PSI initiated a phase II study of a novel oral product for the treatment of asthma.

	Week 3 PSI met an interim enrollment milestone of 600 randomized patients in a phase III study of a novel biological agent in relapsing-remitting multiple sclerosis.

	Week 2 PSI achieved an interim enrollment target of 350 randomized patients in a phase III study of a novel antineoplastic agent in metastatic colorectal cancer (CRC).

	Week 1 PSI initiated enrollment in a phase III study of a novel antibiotic in patients with community-acquired bacterial pneumonia (CABP).

	Week 52 PSI launched a non-interventional study in patients with atrial fibrillation.

	Week 51 PSI completed the active treatment period in a phase III study of a novel dialysis product in patients with chronic kidney disease (CKD).

	Week 50 PSI initiated enrollment in a phase III study of a novel antineoplastic agent in patients with metastatic pancreatic cancer.

	Week 49 PSI initiated enrollment in a phase III study of a novel cancer vaccine in patients with breast cancer.

	Week 48 PSI launched a phase III study of a novel biological agent in patients with chronic lymphocytic leukemia (CLL).

	Week 47 PSI launched a proof-of-concept study of a novel biological agent used in supportive care in pediatric patients with solid tumors.

	Week 46 PSI launched a phase III study of a novel biological agent in patients with a myeloproliferative blood disorder.

	Week 45 PSI initiated enrollment in a phase II study of a novel diagnostic agent in patients with castrate-resistant prostate cancer (CRPC).

	Week 44 PSI completed enrollment in a proof-of-concept study of a novel antineoplastic agent in patients with solid tumors.

	Week 43 PSI met an interim enrollment milestone of 450 randomized patients in a phase III study of a novel biological agent in relapsing-remitting multiple sclerosis.

	Week 41 PSI launched a phase II study of a novel biological product in patients with advanced non-small cell lung cancer (NSCLC).

	Week 42 PSI met an interim enrollment milestone of 400 randomized patients in a phase III study of a novel antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

	Week 40 PSI launched a phase III study of a novel antiviral in patients with chronic hepatitis C.

	Week 39 PSI completed enrollment in a phase III study of a novel biological agent in patients with multiple myeloma.

	Week 38 PSI met an interim enrollment milestone of 400 randomized patients in phase III study of a novel biological agent in relapsing-remitting multiple sclerosis.

	Week 37 PSI met an interim enrollment milestone of 300 randomized patients in a phase III study of a novel biological agent in multiple myeloma.

	Week 36 PSI met an interim enrollment milestone of 350 randomized patients in a phase III study of a novel antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

	Week 35 PSI met an interim enrollment milestone of 350 randomized patients in a phase III study of a novel biological agent in relapsing-remitting multiple sclerosis.

	Week 34 PSI met an interim enrollment milestone of 200 randomized patients in a phase III study of a novel antineoplastic agent in metastatic colorectal cancer (CRC).

	Week 33 PSI launched a phase IV study of a novel antithrombotic agent in patients with atrial fibrillation.

	Week 32 PSI met an interim enrollment milestone of 300 randomized patients in a phase III study of a novel antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

	Week 31 PSI met an interim enrollment milestone of 250 randomized patients in a phase III study of a novel biological agent in multiple myeloma.

	Week 30 PSI met an interim enrollment milestone of 300 randomized patients in a phase III study of a novel biological agent in relapsing-remitting multiple sclerosis.

	Week 29 PSI launched a phase II study of a novel biological agent in patients with advanced non-small cell lung cancer (NSCLC).

	Week 28 PSI met an interim enrollment milestone of 250 randomized patients in a phase III study of a novel biological agent in relapsing-remitting multiple sclerosis.

	Week 27 PSI launched a phase II study of a novel biological agent in patients with metastatic pancreatic cancer.

	Week 26 PSI met an interim enrollment milestone of 200 randomized patients in a phase III study of a novel antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

	Week 25 PSI met an interim enrollment milestone of 150 randomized patients in a phase III study of a novel biological agent in relapsing-remitting multiple sclerosis.

	Week 24 PSI initiated enrollment in a phase II study of a novel biological agent in patients with gastric cancer.

	Week 23 PSI initiated enrollment in a phase III study of a novel antineoplastic agent in patients with advanced non-small cell lung cancer (NSCLC).

	Week 22 PSI met an interim enrollment milestone of 100 randomized patients in a phase III study of a novel antineoplastic agent in metastatic colorectal cancer (CRC).

	Week 21 PSI reached an interim enrollment objective of 300 randomized pediatric patients in a phase III study of a novel antiemetic for the prevention of chemotherapy-induced nausea and vomiting (CINV).

	Week 20 PSI launched a proof-of-concept study of a novel targeted therapy in patients with solid tumors.

	Week 19 PSI initiated enrollment in a phase II study of a novel agent for the treatment of metastatic non-small cell lung cancer (NSCLC).

Full Name

Details